文献速递临床生化临床免疫

胰高血糖素与胃泌酸调节素免疫LC-MS/MS测定的实验室间比对:对糖尿病研究的意义

Interlaboratory Comparison of a Glucagon and Oxyntomodulin Immuno-LC-MS/MS Assay: Implications for Diabetes Research.
PubMed 文献 · Clin Chem · 2026-07-04

该研究在3个实验室间转移并验证了同时测定血浆胰高血糖素和胃泌酸调节素的免疫亲和富集LC-MS/MS方法,评估其对糖尿病患者与非糖尿病样本的检测性能,并与2种FDA注册的商用免疫测定法比较。结果显示该方法在正常范围(1-20 pM)内线性良好,40份样本的实验室间中位不精密度(%CV)胰高血糖素为6.3%(IQR 4.5%),胃泌酸调节素为14.4%(IQR 12.4%);与商用免疫测定法比较,Mercodia的R=0.92,Ansh的R=0.70,回归分析提示各免疫测定法与胃泌酸调节素存在显著交叉反应。

要点

  • LC-MS/MS法可灵敏特异地同时测定胰高血糖素和胃泌酸调节素。
  • 商用胰高血糖素免疫测定法与胃泌酸调节素存在显著交叉反应。
  • 该方法适用于高复杂度临床实验室的研究或患者管理。

核心结论

  • 验证了一种灵敏特异的胰高血糖素和胃泌酸调节素测定方法,可部署于高复杂度临床实验室用于研究或患者管理。
  • 商用胰高血糖素免疫测定法受到胰高血糖素以外分子的显著干扰。

研究设计与样本

  • 方法学验证与实验室间比对研究,在3个实验室间共享标准操作程序并进行方法转移。
  • 评估样本来自糖尿病患者和非糖尿病患者,并与2种商用FDA注册的胰高血糖素免疫测定法进行比较。
  • 采用免疫亲和富集和LC-MS/MS同时测定胰高血糖素和胃泌酸调节素,使用纯合成胰高血糖素作为校准品。

主要发现

  • 方法在正常范围(1-20 pM)内线性良好。
  • 40份样本双份测定,实验室间中位不精密度(%CV)胰高血糖素为6.3%(IQR 4.5%),胃泌酸调节素为14.4%(IQR 12.4%)。
  • 与商用免疫测定法比较,Mercodia的R=0.92(良好一致),Ansh的R=0.70(一般一致)。
  • 使用LC-MS/MS测定的胰高血糖素和胃泌酸调节素浓度预测免疫测定结果的多变量线性回归提示,每种免疫测定法均与胃泌酸调节素存在显著交叉反应。

临床怎么用

  • 该LC-MS/MS方法可在高复杂度临床实验室用于糖尿病研究中α细胞功能的评估或患者管理。
  • 解读商用胰高血糖素免疫测定法结果时需考虑其与胃泌酸调节素的交叉反应干扰。

局限性

  • 原文未明确报告研究的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The quantification of plasma glucagon and oxyntomodulin is important in the assessment of α-cell function, which is impaired in patients with diabetes. We aimed to transfer between laboratories a novel assay that uses liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the sensitive and specific measurement of these highly homologous hormones. METHODS: Simultaneous measurement of glucagon and oxyntomodulin used immunoaffinity enrichment and LC-MS/MS. Immunoenrichment used monoclonal antibodies that are available at-cost to researchers (deposited at the Developmental Studies Hybridoma Bank). Pure synthetic glucagon, characterized for purity and concentration, was used as a calibrant and is available to others. A detailed standard operating procedure was shared between 3 laboratories and the performance of the method was evaluated with samples collected from patients with and without diabetes. Method comparison was made with 2 commercially available, FDA-registered glucagon immunoassays. RESULTS: The method was linear over the normal range (1-20 pM). When measured in duplicate, the median interlaboratory imprecision (%CV) of the measurement of 40 samples was 6.3% (IQR 4.5%) and 14.4% (IQR 12.4%) for glucagon and oxyntomodulin, respectively. Method comparison with commercially available immunoassays demonstrated good (Mercodia, R = 0.92) or fair (Ansh, R = 0.70) agreement. Multivariable linear regression using LC-MS/MS glucagon and oxyntomodulin concentrations to predict immunoassay results indicated significant cross-reactivity of each immunoassay with oxyntomodulin. CONCLUSION: We have validated a sensitive and specific assay for glucagon and oxyntomodulin that can be deployed in high-complexity clinical laboratories for research or the care of patients. Commercially available glucagon immunoassays have significant interference from molecules other than glucagon.

来源:Clin Chem,查看原文。版权归原作者所有。

引用

  1. Moradian A, Becker JO, Nierves LA, et al. Interlaboratory Comparison of a Glucagon and Oxyntomodulin Immuno-LC-MS/MS Assay: Implications for Diabetes Research. Clin Chem. 2026. PMID: 42400596. doi:10.1093/clinchem/hvag078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。